Afgeronde projecten :: hivmonitoring

In dit overzicht vindt u informatie over afgeronde onderzoeken waarbij data van SHM zijn gebruikt. De lijst is gefilterd en toont alleen projecten die beschikbaar zijn voor een breed publiek. De informatie die nu volgt is Engelstalig.

SHM nr	Titel project en publicatie	Auteur(s)
I07010	Efficacy and safety of dose reductions of efavirenz as part of therapeutic drug monitoring Date of Approval: January 22, 2007 Paper: Efavirenz dose reduction is safe in patients with high plasma concentrations and may prevent efavirenz discontinuations. van Luin M, Gras L, Richter C, van der Ende ME, Prins JM, de Wolf F, Burger DM, Wit FW. J Acquir Immune Defic Syndr. 2009 Oct 1;52(2):240-5. Abstract	van Luin M, Gras L, Richter C, van der Ende ME, Prins JM, de Wolf F, Burger DM, Wit FW.
I07058	Nevirapine, nelfinavir and other protease inhibitor side effects during pregnancy Paper: Steady-state nevirapine plasma concentrations are influenced by pregnancy. Nellen JF, Damming M, Godfried MH, Boer K, van der Ende ME, Burger DM, de Wolf F, Wit FW, Prins JM. HIV Med. 2008 Apr;9(4):234-8. Abstract	van der Ende ME, Boer K, Godfried MH, Nellen FJ.
I05011	Atazanavir switch study Date of Approval: October 10, 2004 Paper: Baseline lipid levels rather than the presence of reported body shape changes determine the degree of improvement in lipid levels after switching to atazanavir. van Vonderen MG, Gras L, Wit F, Brinkman K, van der Ende ME, Hoepelman AI, de Wolf F, Reiss P. HIV Clinical Trials. 2009 May-June;10(3):168-80. Abstract	van Vonderen MG, Gras L, Wit F, Brinkman K, van der Ende ME, Hoepelman AI, de Wolf F, Reiss P.
I07020	A longitudinal inter-cohort study on antiretroviral combinations including nevirapine Date of Approval: January 23, 2007 Paper: Safety and efficacy of once-daily nevirapine dosing: a multicohort study. Calmy A, Vallier N, Nguyen A, Lange JM, Battegay M, de Wolf F, Reiss P, Lima VD, Hirschel B, Hogg RS, Yip B, Montaner JS, Wit FW; Swiss HIV Cohort study; HAART Observational Medical Evaluation and Research Cohort; Netherlands ATHENA Observational Cohort. Antivir Ther. 2009;14(7):931-8. Abstract	Calmy A, Vallier N, Nguyen A, Lange JM, Battegay M, de Wolf F, Reiss P, Lima VD, Hirschel B, Hogg RS, Yip B, Montaner JS, Wit FW; Swiss HIV Cohort study; HAART Observational Medical Evaluation and Research Cohort; Netherlands ATHENA Observational Cohort.
I04031	Heterosexual HIV transmission among migrants originating from Surinam, the Netherlands Antilles and Aruba: the role of traveling to the country of origin Date of Approval: July 08, 2004 Paper: Migrants travelling to their country of origin: a bridge population for HIV transmission? Kramer MA, van Veen MG, de Coul EL, Geskus RB, Coutinho RA, van de Laar MJ, Prins M. Sex Transm Infect. 2008 Dec;84(7):554-5. Abstract Paper: HIV Transmission Patterns among The Netherlands, Suriname, and The Netherlands Antilles: A Molecular Epidemiological Study. Kramer MA, Cornelissen M, Paraskevis D, Prins M, Coutinho RA, van Sighem AI, Sabajo L, Duits AJ, Winkel CN, Prins JM, van der Ende ME, Kauffmann RH, Op de Coul EL. AIDS Res Hum Retroviruses. 2010 Oct 7. [Epub ahead of print] Abstract	Prins M, Op de Coul E, Kramer MA, Cornelissen MI, van Sighem A, Sabajo LOA, Duits AJ, Prins JM, Kauffman RH, van der Ende ME.
I07087	Combined use of lopinavir/ritonavir and rifampin in HIV patients coinfected with tuberculosis (TB) D.M. Burger, R. L’homme. Date of Approval: March 23, 2007 Paper: Clinical experience with the combined use of lopinavir/ritonavir and rifampicin. L'homme RF, Nijland HM, Gras L, Aarnoutse RE, van Crevel R, Boeree M, Brinkman K, Prins JM, Juttmann JR, Burger DM. AIDS 2009, 23:863–867. Abstract	Burger DM, L’homme RF.
I04046	Predictors of frequencies; key characteristics of observational data obtained from HIV-infected patients participating in the national cohort on AIDS therapy evaluation in The Netherlands (ATHENA) Date of Approval: July 8, 2004. Paper: The effect on treatment comparisons of different measurement frequencies in human immunodeficiency virus observational databases. Griffin JT, Fraser C, Gras L, de Wolf F, Ghani AC. Am J Epidemiol 2006 Apr 1; 163(7): 676-83. Abstract	Griffin JT, Fraser C, Gras L, de Wolf F, Ghani AC.
I04044	Semi-parametric accelerated failure time regression analysis with application to interval censored HIV/AIDS data Date of Approval: July 8, 2004. Paper: Semi-parametric accelerated failure time regression analysis with application to interval-censored HIV/AIDS data. Xue H, Lam KF, Cowling BJ, de Wolf F. Stat Med 2006 Nov 30; 25(22): 3850-63. Abstract	Xue H, Lam KF, Cowling BJ, de Wolf F.
I04016	The Genotypic Inhibitory Quotient (GIQ) for Lopinavir Date of Approval: April 22, 2004. Paper: The genotypic inhibitory quotient and the (cumulative) number of mutations predict the response to lopinavir therapy. Hoefnagel JG, van der Lee MJ, Koopmans PP, Schuurman R, Jurriaans S, van Sighem AI, Gras L, de Wolf F, Galama JM, Burger DM. AIDS 2006 Apr 24;20(7):1069-1071. Abstract	Hoefnagel JG, van der Lee MJ, Koopmans PP, Schuurman R, Jurriaans S, van Sighem AI, Gras L, de Wolf F, Galama JM, Burger DM.
I07903	Antiretroviral treatment of primary HIV infection Date of Approval: April 15, 2003 This research is continued through a new research proposal with the following title ‘Primo-SHM’ (I08044) which started as from February 2008.I08044	Prins JM, Steingrover R, Kroon FP, van Valkengoed I.
I07015	Nevirapine hypersensitivity reactions study, Paper: Discontinuation of Nevirapine Due to Hypersensitivity Reactions in Patients with Prior Treatment-experience Compared to Treatment-naïve Patients: The ATHENA Cohort Study. Wit FW, Kesselring AM, Gras L, Richter C, van der Ende ME, Brinkman K, Lange JM, de Wolf F, Reiss P. Clin Infect Dis. 2008 Mar 15;46(6):933-40. Abstract	Wit FW, Kesselring AM, Gras L, Richter C, van der Ende ME, Brinkman K, Lange JM, de Wolf F, Reiss P.
I08203	Transmission of antiretroviral drug resistant HIV-1 and HIV-1 subtypes in recently infected and therapy-naive individuals in the Netherlands Date of approval: Oct 21, 2004 Paper: Evolution of transmitted HIV-1 with drug-resistance mutations in the absence of therapy: effects on CD4+ T-cell count and HIV-1 RNA load. Bezemer D, de Ronde A, Prins M, Porter K, Gifford R, Pillay D, Masquelier B, Fleury H, Dabis F, Back N, Jurriaans S, van der Hoek L; CASCADE collaboration. Antiviral Therapy 2006; 11: 173-17. Abstract Paper: Declining trend in transmission of drug-resistant HIV-1 in Amsterdam. Bezemer D, Jurriaans S, Prins M, van der Hoek L, Prins JM, de Wolf F, Berkhout B, Coutinho R, Back NK. Municipal Health Service Amsterdam, The Netherlands. AIDS. 2004 Jul 23;18(11):1571-7. Paper	Coutinho RA, de Wolf F, Prins M.
I17603	Clinical, immunological and virological parameters in a cohort of HIV-2 infected patients in the Netherlands on or off therapy with different antiretroviral regimens Date of approval: April 20, 2004 Paper: Clinical, immunological and virological response to different antiretroviral regimens in a cohort of HIV-2-infected patients. Van der Ende ME, Prins JM, Brinkman K, Keuter M, Veenstra J, Danner SA, Niesters HG, Osterhaus AD, Schutten M. University Hospital Rotterdam, Dijkzigt, Rotterdam, The Netherlands. AIDS. 2003 Jul;17 Suppl 3:S55-61. Paper	van der Ende ME, Schutten M, Osterhaus ADME.
I05515	Defining the prognosis of HIV-1 infected patients treated with potent antiretroviral therapy Date of Approval: Oct 27, 2005	de Wolf F.
I07403	Differential CD4 T-cell response in HIV-1-infected patients using protease inhibitor-based or nevirapine-based highly active antiretroviral therapy Date of Approval: Jan 16, 2003 Paper: Differential CD4 T-cell response in HIV-1-infected patients using protease inhibitor-based or nevirapine-based highly active antiretroviral therapy. Van Leth F, Wit FW, Reiss P, Schattenkerk JK, van der Ende ME, Schneider MM, Mulder JW, Frissen PH, de Wolf F, Lange JM. HIV Med. 2004 Mar;5(2):74-81. Abstract	van Leth F, Wit F, Reiss P, Schattenkerk JKME, van der Ende ME, Schneider MME, Mulder JW, Frissen PHJ, de Wolf F, Lange JMA.
I07303	Tolerance, safety and efficacy of antiretroviral combination therapy in HIV-infected women Date of Approval: Jan 16, 2003 Paper: Nelfinavir and nevirapine side effects during pregnancy. Timmermans S, Tempelman C, Godfried MH, Nellen J, Dieleman J, Sprenger H, Schneider ME, de Wolf F, Boer K, van der Ende ME; Dutch HMF Study Group. AIDS. 2005 May 20;19(8): 795-9. Paper Paper: Highly active antiretroviral therapy (HAART) in HIV-positive pregnant women in the Netherlands, 1997-2003: safe, effective and with few side effects. Tempelman C, Timmermans S, Godfried MH, Dieleman JP, Boer K, van der Ende ME. Ned Tijdschr Geneeskd. 2004 Oct 9;148(41):2021-5.	van der Ende ME, Nellen FJ, Godfried MH, Boer K, Dieleman JP, de Wolf F, Schneider MME.
I10303	TRIESTAN (TReatment Interruption in Early STArters - Netherlands) Date of Approval: Jan 19, 2006 Paper: Effects of active treatment discontinuation in patients with a CD4+ T-cell nadir greater than 350 cells/mm3: 48-week Treatment Interruption in Early Starters Netherlands Study (TRIESTAN). Pogány K, van Valkengoed IG, Prins JM, Nieuwkerk PT, van der Ende I, Kauffmann RH, Kroon FP, Verbon A, Nievaard MF, Lange JM, Brinkman K. J Acquir Immune Defic Syndr. 2007 Apr 1;44(4):395-400. Abstract Presentation: Treatment Interruption in Early Starters in the Netherlands (TRIESTAN): Successful for at Least 36 Weeks. Pogány K, van Valkengoed I, Kroon F, Prins J, Lange J, Brinkman K. At CROI February 2005 12th conference on retroviruses and opportunistic infections, (Foundation for retrovirology and human health, Alexandria, VA, 2005), chap.584, p.267.	Brinkman K, Pogany K, Prins JM, Kroon FP, Wit F, Lange JMA.